The latest cancer treatment is in your medicine cabinet right now
Open up your medicine cabinet and have a look around. You may have the latest cancer treatment front and center — aspirin. Yep. Good ole regular aspirin that costs ~$0.05 per tablet.
The discovery of aspirin’s nature roots dates back to ancient civilizations. Sumerians, Egyptians, and Greeks used willow bark as a pain reliever. The 18th- and 19th-century ushered in a host of developments that led to modern day aspirin. In 1763, English clergyman Edward Stone observed willow bark reduced fevers. In 1828, German chemist Joseph Buchner isolated salicin as the active chemical in willow bark. In 1853, French chemist Charles Gerhardt synthesized salicylic acid, a derivative of salicin. In 1897, German chemist Felix Hoffmann, working for the Bayer company, synthesized acetylsalicylic acid (ASA), a more stable and less irritating form of salicylic acid. He named the new compound “aspirin,” a combination of the words “acetyl” and “spiraea,” a plant related to willow. Bayer patented aspirin on March 6, 1899, and began marketing it as a pain reliever and fever reducer.
Fast forward 126 years, almost exactly to the day. Scientists have now uncovered how aspirin works to stop some cancers such as breast, bowel, and prostate from spreading (known as metastasis.) Metastasis, the spread of cancer cells from primary tumors to distant organs, is the cause of 90% of cancer deaths globally.
When cancer first spreads, there’s a window of opportunity for treatment when cancer cells are particularly vulnerable. By stimulating the immune system during this window of time, aspirin could prevent spread and recurrence in patients with early cancer. The study, published on March 5, 2025 in the journal, Nature, will support ongoing clinical trials in humans, to work out who is most likely to benefit based on the many different aspects of tumors (known as biomarkers.) It’s also important to note that aspirin is known to increase bleeding risk and can cause extreme stomach upset and toxicity so this treatment must only be done under the recommendation and supervision of a medical team.
Professor Rahul Roychoudhuri in the Department of Pathology at the University of Cambridge, who led the work, said, “Despite advances in cancer treatment, many patients with early stage cancers receive treatments, such as surgical removal of the tumor, which have the potential to be curative, but later relapse due to the eventual growth of micro metastases–cancer cells that have seeded other parts of the body but remain in a latent state.
“Most immunotherapies are developed to treat patients with established metastatic cancer, but when cancer first spreads there’s a unique therapeutic window of opportunity when cancer cells are particularly vulnerable to immune attack. We hope that therapies that target this window of vulnerability will have tremendous scope in preventing recurrence in patients with early cancer at risk of recurrence.”
Aspirin is less expensive than antibody-based therapies, so more accessible globally. It also has fewer side effects than many cancer treatments and could therefore be better tolerated by patients to protect and preserve quality of life without compromising other aspects of a person’s health.
I have a long day of medical appointments with my oncology team at NYU’s Perlmutter Cancer Center next week on March 25th. (These are my regular check-ups and include the administration of some of my medications that I have to have done by my medical team.) I’ll absolutely discuss with them the potential of aspirin to help keep me cancer-free, and keep you updated on their response. I love to participate in research studies — not only does it help me, but it also helps me pay forward all of the benefits I’ve received from others who participated in research that make my treatments possible. Curing cancer takes a village, and maybe someday, a daily dose of aspirin.